



# The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence

Ilana Katz Sand<sup>1</sup>

Published online: 16 August 2018  
© The Author(s) 2018

## Abstract

**Purpose of Review** This review seeks to examine current research related to the role of diet in multiple sclerosis (MS).

**Recent Findings** Recent research in preclinical models, epidemiologic studies, and limited prospectively followed cohorts provide preliminary evidence that dietary factors influence MS incidence, disease course, and symptomatology. Current evidence for the effects of fatty acids, fruits and vegetables, whole grains, dairy, and salt are reviewed. Dietary patterns including overall diet quality, caloric restriction, McDougall diet, Paleolithic diet, and Mediterranean diet are discussed. Hypotheses regarding potential mechanistic connections underlying observed effects are also presented.

**Summary** Several individual dietary components and patterns demonstrate potential for significant impact in MS. Definitive answers regarding the ability of diet to act as a disease modifier in MS will ultimately require large-scale clinical trials. Continued prospective studies and clinical trials to further advance this line of research are warranted.

**Keywords** Multiple sclerosis · Diet · Nutrition · Experimental autoimmune encephalomyelitis · Mechanism · Environment

## Introduction

Multiple sclerosis (MS) is a chronic central nervous system disease with inflammatory and neurodegenerative components. Most patients initially present with a relapsing-remitting course defined by the acute onset of focal neurologic deficits and corresponding focal inflammatory changes visible on MRI. Episodes reflect inflammatory demyelinating lesions in the optic nerves, brain, and spinal cord that result in symptoms such as loss of vision, weakness, numbness, gait difficulty, and bowel and bladder disturbances [1]. Many MS patients also experience more global symptoms such as fatigue, depression, and cognitive changes. In addition to inflammatory lesion formation, atrophy indicative of neurodegeneration begins early in the disease course [2] and drives disability over time [3]. Approximately 10% of MS patients demonstrate

disease progression characterized by insidious neurologic decline from the outset (primary progressive MS) while a much larger subset begins with a relapsing-remitting course but develops symptoms of gradual decline later on (secondary progressive MS) reflective of worsening neurodegeneration even in the absence of new inflammatory lesions [4].

MS is thought to result from a combination of genetic predisposition and environmental influences [5, 6]. Established environmental risk factors for MS include low vitamin D levels [7], sun exposure [8], smoking [9], and viral exposures [10]. Relevant to this review, obesity, particularly during adolescence, has also been identified as a risk factor for MS [11]. In addition to the importance of environmental factors in risk of disease onset, there is significant variability among MS patients regarding clinical disease course. This observation has resulted in a search for modifiable environmental factors that might be manipulated to positively impact outcomes once the diagnosis of MS has been established. Many of the above risk factors for MS development have also been demonstrated to impact clinical course [12–16]. However, a significant portion of environmental risk for the development of MS as well as variability in the clinical MS disease course currently remains unexplained. Epidemiologic research dating back many years has suggested dietary factors may be important in MS [17]. While large-scale clinical trial data is not yet

---

This article is part of the Topical Collection on *Neurological Disease and Cognitive Function*

---

✉ Ilana Katz Sand  
ilana.katzsand@mssm.edu

<sup>1</sup> Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Suite 1138, New York, NY 10029, USA

available, a growing body of literature including epidemiologic, preclinical, and observational studies as well as small clinical trials suggests the importance of dietary factors in the risk of MS onset and clinical course. The diet is a major source of environmental interaction and dietary metabolites exert far-reaching systemic effects, rendering diet an attractive candidate as a potential environmental mediator in MS. This review will begin with a discussion of potential underlying mechanisms for the effects of diet as a disease modifier followed by presentation of the current literature on various dietary factors in MS. Potential effects of diet on MS symptoms will also be discussed.

## Multiple Sclerosis Pathophysiology: Opportunities for Dietary Effects

There are at least three overarching aspects of MS pathophysiology that represent opportunities for influence on disease outcomes. Interventions may (1) modulate the inflammatory state, (2) protect against neurodegeneration, or (3) promote nervous system repair.

The pathophysiology of MS is complex and incompletely understood [18]. Supporting the hypothesis that MS is at least in part related to peripheral autoimmunity, genome-wide association studies have mapped MS risk to loci related to the immune system [19, 20]. MS was once considered strictly related to T cell dysregulation; however, many components of the innate and adaptive immune systems have now been shown to be relevant to MS immunopathology [18, 21]. The complexity of MS pathophysiology is reflected by the myriad therapies approved for relapsing MS, each with a distinct immunomodulatory mechanism yet all effective at preventing clinical disease relapses and new lesions on MRI. Dietary factors that are able to promote regulatory as opposed to inflammatory immune cell differentiation and cytokine production therefore have the potential ability to reduce new inflammatory lesion formation and clinical relapses utilizing pathways similar to traditional disease-modifying therapies for MS.

Current MS disease-modifying therapies are relatively effective at reducing new lesions and clinical relapses; however, more elusive have been agents that halt underlying neurodegeneration. As described, approximately 10% of patients present with progressive neurological decline from the outset. Even in patients with a relapsing-remitting phenotype, the neurodegenerative aspect of the disease is present early on and is in fact detectable before the disease becomes clinically apparent [22]. Histology in chronic MS demonstrates evidence of smoldering localized inflammation, chronic demyelination, and axonal and neuronal damage at the site of MS lesions as well as more broadly, affecting both white matter and gray matter [23]. According to a model with increasing

support, oxidative stress causes mitochondrial dysfunction resulting in chronic energy insufficiency, eventually leading to ion channel redistribution causing cell damage and eventually cell death [24]. Effective disease-modifying therapies in relapsing patients slow but do not halt this neurodegenerative process. There is therefore a great need for the identification of strategies that are able to protect against chronic demyelination and axonal/neuronal loss. Dietary factors that dampen resident CNS inflammation, combat oxidative stress, or protect mitochondria may help prevent chronic demyelination and axonal/neuronal damage.

Also currently under study are multiple strategies aimed at remyelination and repair. Remyelination of demyelinated axons may be helpful with regard to restoring function as well as with protection of previously denuded axons from further damage. The process of remyelination occurs spontaneously however is highly variable between individuals and efficiency decreases over time [25]. Oligodendrocyte precursor cells (OPCs) capable of remyelination are present in the adult brain; however, inhibitors of OPC differentiation in the local environment hinder this process [26]. Therapies aimed at manipulating the CNS environment to favor OPC differentiation and encourage remyelination are currently in clinical trials [27]. Dietary factors that are able to influence remyelination and repair could certainly be of benefit in MS.

## Mechanisms for Dietary Effects in Multiple Sclerosis

There are several theoretical pathways through which dietary factors may exert systemic influence resulting in beneficial effects on inflammation, neuroprotection, and repair in MS. The first is through indirect effects on metabolic factors. Diet has a significant impact on body weight, cholesterol levels, and other vascular risk factors that affect MS risk and disease course [11, 28–33]. Separating the relative contribution of diet from these other factors is challenging and will require targeted studies. A detailed discussion of the role of these metabolic factors in MS has been completed elsewhere [34, 35]; this review will focus on direct effects of diet in MS. These include effects mediated by dietary metabolites derived directly from food, dietary induction of metabolite production by gut microbiota, and diet-mediated changes in gut microbial composition.

Whether metabolites arise directly from the diet or are produced by gut bacteria in response to ingestion of particular foods, they exert effects through shared mechanisms. These include G-protein coupled receptor (GPCR) signaling as well as epigenetic regulation of gene expression through inhibition of histone deacetylases (HDAC) and effects on transcription factors such as the aryl hydrocarbon receptor (AhR) [36]. In addition to their presence on intestinal epithelium and tissues

relevant to metabolism such as adipose tissue, “metabolite-sensing” GPCRs are expressed by various immune cells. Potentially important for observed effects in MS, for example, GPR120 recognizes omega-3 fatty acids [37], GPR35 recognizes tryptophan metabolites [38], and GPR43 recognizes short-chain fatty acids (SCFAs) [39]. Interestingly, one signaling pathway engaged by many GPCRs is mediated by  $\beta$ -arrestin-2, resulting in downstream inhibition of NF- $\kappa$ B and other anti-inflammatory effects [36]. Regarding epigenetic regulation, acetylation of histones mediated by HDAC inhibitors largely results in transcriptional activation. Relevant to MS, HDAC inhibitors have generally been demonstrated to have anti-inflammatory effects including increased Foxp3 expression and increased numbers of Foxp3+ Treg cells [40]. Butyrate and the other SCFAs are natural HDAC inhibitors; other dietary metabolites may act through these pathways as well. The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor stimulated by a broad array of small molecules including many that arise from environmental exposures. AhR activation is associated with a variety of anti-inflammatory effects on the innate and adaptive immune systems [41]. Particularly pertinent for MS, dietary-derived metabolites are able to cross the blood-brain barrier and activate AhR on astrocytes resulting in targeted, local effects in the CNS [42, 43••]. The most well-characterized AhR agonists relevant to MS are tryptophan and its metabolites. Flavonoids are also able to act as AhR agonists (both discussed further below).

Some of these metabolites are derived directly from the diet whereas others are produced by resident commensal flora, the gut microbiota. Studies in experimental autoimmune encephalomyelitis (EAE; MS animal model) and in MS demonstrate important links to gut microbial composition [44••, 45, 46, 47•, 48–50] and suggest manipulation of microbiota by diet may be of benefit [51]. Dietary factors induce the production of particular metabolites by gut microbiota as well as more indirectly affect metabolite production by affecting gut microbial composition. In addition to effects mediated by metabolites, gut microbiota directly interact with the gut’s resident immune system. Pattern recognition receptors (e.g., toll-like receptors) on intestinal epithelial and dendritic cells recognize microorganism-associated molecular patterns and subsequently influence T cell differentiation in mesenteric lymph nodes through effects on antigen presentation [52, 53]. As different microorganisms induce diverse effects, influences on microbial composition are significant determinants of systemic impact. Many factors affect gut microbial composition including mode of birth and breastfeeding [54], infectious and antibiotic exposure [55, 56]; however, the biggest long-term driver is diet [57•, 58], thereby providing an important potential mechanistic link in MS.

## Evidence for the Role of Specific Dietary Components in Multiple Sclerosis

### Fats

#### Saturated Fat

Saturated fats, defined by the presence of the maximum number of hydrogen atoms bound to each carbon atom in the fatty acid chain, have been linked to inflammation and largely blamed for the rise in cardiovascular disease in developed countries [59]. Several mechanisms are potentially relevant to MS. Though recent questions have been raised, it is generally accepted that intake of saturated fats increases LDL cholesterol [59], which is associated with poor outcomes in MS [30–33]. Saturated fats directly impact the innate immune system through activation of pro-inflammatory toll-like receptors, leading to downstream consequences including increased NF- $\kappa$ B [60]. They may also indirectly affect these pathways by increasing endotoxin levels [61]. Effects on the adaptive immune system are also likely important. In an animal model of MS, mice fed a “Western” high fat diet exhibited worsened clinical scores associated with increased T cell and macrophage infiltration and spinal cord expression of pro-inflammatory cytokines IL-1B, IL-6, and IFN $\gamma$  [62]. Interestingly, fatty acid chain length seems to be an important determinant of ultimate effects. Long-chain fatty acids (LCFA) such as those commonly found in processed foods featured in “Western” diets promote the differentiation of naïve T cells into pro-inflammatory T<sub>H</sub>1 and T<sub>H</sub>17 cells, seemingly mediated by members of the MAP kinase family including p38 and JNK1 [63]. Mice fed an LCFA-rich diet exhibited more severe EAE compared to those fed a standard diet. In contrast, short-chain fatty acids (SCFAs) have been demonstrated to favor differentiation of regulatory T cells with resulting production of anti-inflammatory cytokines [63, 64]. Rather than being ingested in the diet, SCFAs are largely produced by intestinal microbiota in response to dietary intake of fiber-rich plant-based foods and are therefore discussed below (see “Fruits, Vegetables, and Whole Grains”).

From an epidemiologic standpoint, Swank observed geographic variations in MS incidence that could be related to intake of fats, particularly fats derived from animal products such as meat and dairy, first published in 1950 [17, 65]. He subsequently led a prolonged study that began in 1951 when 144 MS patients agreed to follow a diet with reduced saturated fat (< 20 g/day) intake. Participants were later classified as “good dieters” if they continued following this recommendation or “poor dieters” if they consumed more than 20 g of saturated fats per day. Clinical follow-up continued for many subjects through 34 years [66•] and for a smaller group through 50 years [67]. Those who adhered to the diet showed significantly less disability and had lower mortality rates than

those who did not. However, lack of randomization or measurement of potential confounding factors makes these results difficult to interpret. Still, these are interesting observations that warrant follow-up in the modern research era.

More recently, a prospective study in pediatric MS with rigorously collected disease information from 219 participants followed for a median of nearly 2 years noted an association between energy intake from fat and relapse rate (adjusted hazard ratio for 10% increase in energy intake from fat 1.56,  $p = 0.027$ ) [68••]. Notably, the same increase in energy intake from saturated fat *tripled* this risk (adjusted hazard ratio for 10% increase in energy intake from saturated fat 3.37,  $p = 0.009$ ). These associations remained after adjustment for potential confounders including age, gender, ethnicity, socioeconomic status, disease duration, use of MS disease-modifying therapy, total energy intake, and BMI.

To date, there have been no prospective controlled trials focusing on saturated fat intake, though the McDougall diet, a very low-fat, plant-based diet (discussed below) is currently being investigated as a potential strategy to manage fatigue in MS.

### Polyunsaturated and Monounsaturated Fats

Polyunsaturated fatty acids (PUFAs) contain multiple double bonds within the fatty acid chain and are found in foods such as fish, walnuts, and flax seeds. In particular, there is high interest in omega-3 fatty acids (first double bond at the third carbon position), especially the largely plant-derived alpha-linolenic acid (ALA) and largely marine-derived eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). PUFAs decrease inflammation through conversion into the anti-inflammatory prostaglandins E1 and E2, with downstream effects on cytokine production, leukocyte migration, and other immune system components [69]. Animal studies have demonstrated beneficial effects of PUFAs on EAE including decreased production of inflammatory cytokines and induced peroxisome proliferator-activated receptors (PPAR) in CNS infiltrating T cells [70, 71]. In addition to immunomodulatory effects, animal models suggest PUFAs prevent demyelination and promote neuroprotection and remyelination. In a toxic demyelination animal model of MS (cuprizone), pretreatment of rats with EPA resulted in decreased weight loss and increased whole brain cerebroside content [72]. Mice treated with cuprizone and fed a salmon diet showed smaller lesion volume, less demyelination, and enhanced remyelination in the corpus callosum compared to controls [73].

Epidemiologic studies relating to PUFA intake in MS patients have shown conflicting results. A prior study utilizing the Nurses' Health Study I and II cohorts that identified 195 incident cases of MS among nearly 200,000 enrollees noted a non-significant trend toward an inverse relationship between

ALA intake and MS incidence [74]. A follow-up study with extended observation period identified 479 incident MS cases and did note a significant inverse association between both total PUFA intake and ALA and MS risk (HR top vs. bottom quintile 0.67 and 0.61, respectively) [75]. However, other studies suggest the importance of marine-based PUFA intake. A Swedish case-control study found a decreased incidence of MS among those who reported high fatty fish intake (adjusted odds ratio 0.82) [76]. Similarly, an Australian study found significantly decreased risk of a first clinical demyelinating event among those who reported high intake of omega-3 fatty acids (adjusted odds ratio 0.61) especially when these were marine rather than plant derived (adjusted odds ratio 0.54) [77]. An additional study noted a link between fresh fish intake and onset of MS, independent of vitamin D levels [78].

Clinical trials regarding PUFA intake have yielded inconsistent results [79–83]. Notably, trials conducted thus far have largely been related to PUFA supplements rather than foods though some have also included dietary recommendations such as a study of 31 MS patients randomly assigned to supplement a low-fat diet with fish oil vs. olive oil supplement [83].

Monounsaturated fats (MUFAs), with a single double bond in the fatty acid chain, are found in foods such as olive oil, avocados, and certain nuts. To date, there has been little experimental work directly related to monounsaturated fatty acid intake and MS onset or disease course. However, they are of potential interest in MS given the established benefits of Mediterranean-style diet in cognitive aging [84, 85•] given parallels with MS as a neurodegenerative disease. A pilot clinical trial of a modified Mediterranean diet high in PUFAs and MUFAs (see below) is currently underway.

### Dairy

Vitamin D deficiency is a risk factor for the development of MS [7, 86] and also a negative prognostic factor in MS [87]. Given that dairy products are typically fortified with vitamin D, a negative association between dairy intake and MS risk might be expected. However, work utilizing the Nurses' Health Study cohorts showed an increased risk for developing MS among women with high intake of whole milk during adolescence [88]. Women who consumed whole milk 3 or more times per day had a 47% increased risk of developing MS compared to those who consumed < 1 serving per day. Several hypothetical mechanisms may explain this finding. MS patients have showed abnormally heightened T cell responses to milk antigens, differing at particular epitopes from patients with type 1 diabetes and those without autoimmune disease in both children [89] and adults [90]. The milk protein butyrophilin has been implicated through antigenic mimicry with myelin oligodendrocyte glycoprotein in EAE [91] as well as in MS patients [92]. Gut microbiota may also contribute to

these effects. For example, in an animal model of inflammatory bowel disease, a high milk fat diet was associated with increased incidence and severity of colitis, linked to the proliferation of *Bilophila wadsworthia* and induction of a  $T_H1$  immune response [93].

Within the HOLISM (Health Outcomes in a Sample of people with MS) study, 2047 patients with confirmed MS completed a dietary questionnaire in addition to providing information on MS status [94•]. Participants who reported not consuming dairy were less likely to report recent disease activity and reported higher health-related quality of life compared to those who reported consuming dairy. In contrast, a study utilizing the North American Research Committee on MS (NARCOMS) registry noted an inverse relationship between total dairy intake and disability severity (top vs. bottom quintile, for severe vs. mild disability OR = 0.77,  $p = 0.009$ ) [95••]. Notably, these studies were not able to distinguish between different types of dairy.

### Fruits, Vegetables, and Whole Grains

In the HOLISM study described above, higher intake of fruits and vegetables was associated with reduced levels of patient-reported disease activity and disability [94•]. The prospective pediatric MS study discussed above that noted an increased risk of relapse relating to increased saturated fat intake also noted a reduction in relapse rates with increasing intake of vegetables [68••]. Excluding potatoes and legumes, a one-cup equivalent increase in vegetable intake decreased the risk of relapse by 50% (hazard ratio 0.50,  $p = 0.024$ ).

A pilot study evaluated effects of a high vegetable/low protein diet (HV/LP,  $n = 10$ ) compared to a typical “Western diet” (WD,  $n = 10$ ) in MS patients for 12 months [96]. As compared with WD, the HV/LP group showed a decrease in pro-inflammatory IL-17+ and PD-1+ T cells and an increase in anti-inflammatory PD-L1+ monocytes. In analyses of gut microbiota, the family *Lachnospiraceae* was noted to be more abundant in the HV/LP group compared to the WD group. Within the HV/LP group only, *Lachnospiraceae* abundance was correlated with (anti-inflammatory) IL-10+ and TGF $\beta$ + monocytes and Treg cells.

Little work has been completed with relation to whole grains; however, they are included here because a recent study suggests an association with MS disease course and there is a potential mechanistic connection that also applies to fruits and vegetables that are high in fiber. The NARCOMS study described above noted an inverse relationship between whole grain intake and MS-related disability [95••]. Participants in the top vs. bottom quintile of whole grain consumption had lower odds of severe vs. mild disability (odds ratio 0.78,  $p = 0.02$ ).

A mechanistic link may lie in the capacity for gut microbiota to ferment high fiber foods (certain grains, vegetables,

fruits) to short-chain fatty acids (SCFAs). SCFAs favor immunomodulation by promoting intestinal epithelial cell integrity, inducing the differentiation of Tregs [64], and reducing the production of pro-inflammatory cytokines and chemokines, among other effects, mediated through activation of GPCRs and HDAC inhibition [97]. In EAE, pretreatment with the SCFA propionic acid (PA) ameliorated the disease course, with observed increase in production of the anti-inflammatory cytokine IL-10 and in the number of Foxp3 + Tregs [63]. Interestingly, the transfer of Tregs from PA-treated mice resulted in improved clinical EAE course and histological markers of EAE severity compared to transfer of similar number of Tregs from untreated mice, consistent with important effects of PA on Treg function as well as number.

Other mechanisms may explain the potential link between the intake of fruits and vegetables and MS. For example, cruciferous vegetables provide the essential amino acid tryptophan. Tryptophan’s metabolites, generated by the diet directly as well as by gut microbiota, activate the aryl hydrocarbon receptor (AhR). Through AhR, these metabolites have multiple actions relevant to the peripheral immune system including induction of FoxP3+ Tregs (direct effects on transcription and indirect effects through dendritic cell modulation) and IL-10-producing type 1 regulatory T cells (Tr1) as well as interference with  $T_H17$  cell differentiation [41]. In addition, several of these metabolites are able to cross the blood-brain barrier and activate AhR on astrocytes [43••]. AhR interaction with SOCS2 inhibits NF- $\kappa$ B, ultimately inhibiting local monocyte recruitment and activation, microglial activation, and neurotoxicity [42, 43••]. These effects on the local CNS environment make further investigation of this pathway, particularly regarding the elusive neurodegenerative component of MS, highly significant.

Flavonoids, phytopigments found in fruits and vegetables (and other foods such as coffee and tea) representing the most abundant class of polyphenols, are also AhR agonists [98]. They act through a variety of other mechanisms relevant to immunomodulation and neurodegeneration as well [99, 100••]. Studies of many different flavonoid compounds have demonstrated effectiveness in MS animal models including attenuation of EAE [101, 102], neuroprotection [103, 104], and even promotion of remyelination [105, 106]. However, it is important to note that studies in MS models have largely related to flavonoid compounds rather than foods. Positive effects of foods and food extracts such as strawberries, spinach, and blueberries have been demonstrated in other neurodegenerative diseases [107, 108], and one study of freeze-dried blueberries in EAE showed a protective effect [109].

### Salt

Preclinical studies have suggested potential adverse effects of a high salt diet in MS. Pro-inflammatory  $T_H17$  cell

differentiation is induced by high salt intake modulated through serum glucocorticoid kinase 1 (SGK1) [110]. T<sub>H</sub>17 cells that develop in a high salt environment demonstrate a more pathogenic phenotype and mice fed a high salt diet exhibit worsened course of EAE [111]. Translating this work into humans, investigators estimated dietary sodium intake in 70 relapsing remitting MS patients utilizing a single spot urine sample and then followed them for 2 years [112]. Compared to those in the low sodium intake group, those with medium or high intake had clinical relapse rates 2.75- and 3.95-fold higher, respectively. Similar results were noted in a validation cohort of 52 patients.

However, additional studies have not confirmed these findings. A case-control study in pediatric MS using a food frequency questionnaire to estimate dietary sodium intake found no association with MS risk among 170 MS cases and 331 controls [113]. An observational study utilizing the same pediatric MS network found no association between sodium intake and risk of relapse among 174 relapsing remitting MS patients followed for a median of 1.8 years [114]. An additional study in adults utilized stored 24 h urine samples from the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) trial in which over 400 patients with an initial MS relapse were randomized to be treated with interferon or placebo for 2 years followed by a 3-year extension phase resulting in a cohort with approximately 5 years of follow-up [115]. Patients had a median of 14 urine samples collected over the study period from which dietary sodium could be estimated. There was no association between estimated dietary sodium intake and relapse rates or MRI outcomes in this cohort.

There are currently no published clinical trials specifically aimed at reduction of sodium intake in MS. A study examining effects of high vs. low salt diet on T<sub>H</sub>17 and regulatory T cells in MS patients and healthy controls is currently recruiting (NCT02282878).

## Dietary Patterns in Multiple Sclerosis

In considering the effects of macro or micronutrients and singular foods or food groups, it is important to note that these individual components are not ingested in isolation. Rather, the diet is comprised of many components ingested together as part of an overall program and there are likely significant interactions. Therefore, examination of the effects of global dietary patterns is extremely important.

## Overall Dietary Quality

Two studies have leveraged existing MS registries to evaluate potential associations between overall diet quality and MS-related disability and symptomatology. Within the HOLISM

(Health Outcomes in a Sample of people with MS) study, as described above, 2047 patients with confirmed MS completed the Diet Habits Questionnaire (DHQ) as part of a comprehensive survey including information on relapse rate, disability status, and quality of life [94•]. The study noted that every 10-point increase on the DHQ (overall score ranging from 0 to 50, higher scores indicating higher quality diet) was associated with a 30% less likelihood of higher disability level. Higher DHQ scores were also significantly associated with better physical and mental health-related quality of life (HRQOL). Similarly, 6989 participants in the North American Research Committee on MS (NARCOMS) Registry, as described above, completed a dietary screener questionnaire (DSQ) in addition to providing information on recent relapses, progression, and disability [95••]. Participants in the top quintile of diet quality score were at 20% lower odds of higher disability scores compared to those in the bottom quintile. Higher diet quality was also linked to decreased odds of more severe depressive symptoms, after adjusting for disability status.

## Caloric Restriction

Caloric restriction has gained attention in diverse fields in medicine, particularly in aging [116]. Observations in the aging literature including increase in endogenous corticosteroid production, decrease in inflammatory cytokines, and increase in neurotrophic factors led to initial experiments demonstrating that rats fed a severely calorie-restricted diet (66% food restriction) were protected from the development of EAE [117, 118]. Further experiments with 40% calorie restricted diet in mice showed decreased EAE severity as well as reduced inflammation, demyelination, and axonal damage [119].

There are obvious challenges to translating significant long-term caloric restriction to humans. A potential solution is the use of intermittent caloric restriction, which has also been demonstrated as beneficial in EAE [120, 121]. Mice fed three cycles of a “fasting mimicking” diet (FMD; very low calorie diet lasting 3 days every 7 days) exhibited delayed EAE onset, reduced EAE incidence, and decreased EAE severity [121]. These clinical findings were accompanied by reduced immune cell infiltration and demyelination in the spinal cord on histology. Lymphocytes isolated from draining lymph nodes and spleens showed decreases in T<sub>H</sub>1 and T<sub>H</sub>17 cells and increase in Treg cells in mice fed FMD compared to controls. FMD also protected oligodendrocytes from apoptosis and stimulated oligodendrocyte regeneration and differentiation suggesting an important impact on neuroprotection and repair. These effects were confirmed to be present independent of inflammation, demonstrated through use of a cuprizone model (toxic rather than inflammatory demyelination model).

Toward translating this work to MS patients, a pilot clinical trial randomized 60 relapsing remitting MS patients to a

control diet for 6 months, ketogenic diet (KD) for 6 months, or single cycle of modified FMD for 7 days followed by Mediterranean diet for 6 months [121]. The diets were well tolerated, and participants adhered to them well. Participants assigned to FMD and KD had higher health-related quality of life scores at 3 months compared to controls.

A current pilot study is evaluating feasibility and effects of continuous and intermittent caloric restriction compared to controls for approximately 1 year in MS patients (NCT02647502).

### McDougall Diet

The McDougall Diet is a very low-fat (10% of calories from fat) diet consisting mostly of starchy plant-based foods as well as other vegetables and fruits. No animal products or oils are permitted. In a recent study, 61 participants with relapsing remitting MS were randomized to follow the McDougall diet or participate as a wait-list control for 12 months [122]. The primary end point, the number of new T2 lesions on MRI, was not satisfied; however, notably the study was powered to detect only a very large effect. There were no differences in clinical relapse rates. There was a significant impact on fatigue, though much of the effect was attributable to weight loss. A larger randomized trial of this diet for fatigue is currently underway (NCT03322982).

### Paleolithic Diet

Paleolithic diets have become popular in recent years, both for the general population and among people with MS. While there is some variability regarding allowable foods, Paleolithic diets generally emphasize consumption of lean meats including organ meats, fish, vegetables, and fruits and typically do not permit consumption of dairy or grain products. Despite much attention in the lay literature, to date, there are few scientific studies incorporating a Paleolithic diet for MS. A multimodal intervention including a program of a modified Paleolithic diet, dietary supplements, and a physical exercise program along with electrical stimulation and meditation significantly improved fatigue in patients with secondary progressive MS [123]. This was an open label pilot study that enrolled 10 subjects, only 6 of whom completed the study with good adherence. Additional studies are currently underway (NCT02687919, NCT02914964).

### Mediterranean Diet

There has been little work on Mediterranean-style diets in MS. However, the preliminary evidence reviewed above regarding the role of various dietary components suggests that this type of diet may be of benefit. Mediterranean-style diets are low in saturated fats, high in polyunsaturated and monounsaturated

fats (especially fish and olive oil), high in fruits and vegetables, and low in processed foods implying low salt content. Additional support for further study of this pattern in MS comes from the aging literature, where level of adherence to Mediterranean diet has been associated with structural measures of neurodegeneration [85•] and the presence of Alzheimer's disease or mild cognitive impairment [124], as well as related to degree of cognitive decline longitudinally [124]. A pilot clinical trial of a modified Mediterranean diet in MS is currently underway (NCT02986893).

### Limitations of Current Dietary Research in Multiple Sclerosis and Future Directions

Research regarding the role of diet in multiple sclerosis is advancing but currently remains limited. Few studies have been prospective with rigorously collected outcomes, and the few clinical trials that have been conducted have not been of sufficient size or length to adequately assess efficacy. Moving this field of research forward presents several challenges. Further work needs to be done regarding assessment tools for recording dietary habits in MS patients. Epidemiologic and observational studies of diet are confounded by other behaviors such as smoking and exercise. These can be accounted for in statistical models, but these methods are imperfect and the possibility of unmeasured confounders always exists.

Regarding clinical trials, the goal is to hold their design to the same rigorous standards applied to pharmaceuticals. However, this is rather difficult. Participants must be willing to volunteer to be randomized; MS patients who are willing to agree to potentially make a big dietary change may be disappointed by assignment to a control group which may result in dropouts and crossovers. Given the nature of the intervention, blinding of participants is not possible. Appropriate end points present another challenge. For example, patients with relapsing MS are likely to be on effective MS disease-modifying immunomodulatory therapies, reducing the ability to detect effects of diet on relapse rates and new MRI lesions. The research community is still addressing optimal end points to be used in trials of progressive MS.

### Conclusion

Multiple sclerosis incidence and disease course are clearly influenced by environmental factors. While some factors are well described, the contribution of other mediators has not been fully elucidated. The initial epidemiologic investigations regarding a potential role for diet in MS date back many years. More recently, preclinical models, epidemiologic research, a small number of prospective studies, and limited clinical trials

suggest the importance of various dietary factors in MS. Mechanistic experiments highlight potential effects of diet on both immunomodulatory and neurodegenerative processes in MS. Further research on this topic, ranging from continued basic science studies to clinical trials, is currently ongoing.

## Compliance with Ethical Standards

**Conflict of Interest** Ilana Katz Sand declares that she has no conflict of interest.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Katz SI. Classification, diagnosis, and differential diagnosis of multiple sclerosis. *Curr Opin Neurol.* 2015;28(3):193–205. <https://doi.org/10.1097/WCO.0000000000000206>.
2. Calabrese M. Cortical atrophy is relevant in multiple sclerosis at clinical onset. *J Neurol.* 254(9):1212–20. <https://doi.org/10.1007/s00415-006-0503-6>.
3. Fisniku LK. Gray matter atrophy is related to long-term disability in multiple sclerosis. *Ann Neurol.* 64(3):247–54. <https://doi.org/10.1002/ana.21423>.
4. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology.* 2014;83(3):278–86. <https://doi.org/10.1212/WNL.0000000000000560>.
5. Hedström AK. Environmental factors and their interactions with risk genotypes in MS susceptibility. *Curr Opin Neurol.* 2016a;29(3):293–8. <https://doi.org/10.1097/WCO.0000000000000329>.
6. Olsson TT. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. *Nat Rev Neurol.* 13(1):25–36. <https://doi.org/10.1038/nrneurol.2016.187>.
7. Munger KL. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA.* 296(23):2832–8. <https://doi.org/10.1001/jama.296.23.2832>.
8. van der Mei IAF. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. *BMJ (Clinical research ed).* 327(7410) <https://doi.org/10.1136/bmj.327.7410.316>.
9. Hedström AK. Smoking is a major preventable risk factor for multiple sclerosis. *Mult Scler.* 2016b;22(8):1021–6. <https://doi.org/10.1177/1352458515609794>.
10. Thacker E. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. *Ann Neurol.* 59(3):499–503. <https://doi.org/10.1002/ana.20820>.
11. Hedstrom AK, Lima Bomfim I, Barcellos L, Gianfrancesco M, Schaefer C, Kockum I, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. *Neurology.* 2014;82(10):865–72. <https://doi.org/10.1212/WNL.0000000000000203>.
12. Simpson S. Sun exposure across the life course significantly modulates early multiple sclerosis clinical course. *Front Neurol.* 2018;9.
13. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. *Neurology.* 2012;79(3):261–6. <https://doi.org/10.1212/WNL.0b013e31825fdec7>.
14. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. *Ann Neurol.* 2012;72(2):234–40. <https://doi.org/10.1002/ana.23591>.
15. van der Vurst de Vries RM. Smoking at time of CIS increases the risk of clinically definite multiple sclerosis. *J Neurol.* 2018; <https://doi.org/10.1007/s00415-018-8780-4>.
16. Briggs FBFB. Smokers with MS have greater decrements in quality of life and disability than non-smokers. *Mult Scler.* 2017 1352458516685169. <https://doi.org/10.1177/1352458516685169>.
17. Swank RL, Lerstad O, Strom A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. *N Engl J Med.* 1952;246(19):722–8.
18. Dendrou CA. Immunopathology of multiple sclerosis. *Nat Rev Immunology.* 15(9):545–58. <https://doi.org/10.1038/nri3871>. **Excellent review of multiple sclerosis pathophysiology.**
19. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature.* 2011;476(7359):214–9. <https://doi.org/10.1038/nature10251>.
20. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. *Lancet Neurol.* 2014;13(7):700–9. [https://doi.org/10.1016/S1474-4422\(14\)70041-9](https://doi.org/10.1016/S1474-4422(14)70041-9).
21. Hemmer B. Role of the innate and adaptive immune responses in the course of multiple sclerosis. *Lancet Neurol.* 14(4):406–19. [https://doi.org/10.1016/S1474-4422\(14\)70305-9](https://doi.org/10.1016/S1474-4422(14)70305-9).
22. Rojas JI, Patrucco L, Míguez J, Besada C, Cristiano E. Brain atrophy in radiologically isolated syndromes. *J Neuroimaging.* 2015;25(1):68–71. <https://doi.org/10.1111/jon.12182>.
23. Friese MA. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. *Nat Rev Neurol.* 10(4):225–38. <https://doi.org/10.1038/nrneurol.2014.37>. **Excellent review of neurodegenerative aspect of multiple sclerosis.**
24. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? *Mitochondrial Dysfunction.* 2010;1802(1):66–79. <https://doi.org/10.1016/j.bbadis.2009.07.002>.
25. Goldschmidt T. Remyelination capacity of the MS brain decreases with disease chronicity. *Neurology.* 72(22):1914–21. <https://doi.org/10.1212/WNL.0b013e3181a8260a>.
26. Kuhlmann T. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. *Brain (London, England : 1878).* 131:1749–58. <https://doi.org/10.1093/brain/awn096>.
27. Stangel M. Achievements and obstacles of remyelinating therapies in multiple sclerosis. *Nat Rev Neurol.* 13(12):742–54. <https://doi.org/10.1038/nrneurol.2017.139>.
28. Langer-Gould A, Brara SM, Beaber BE, Koenick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. *Neurology.* 2013;80(6):548–52. <https://doi.org/10.1212/WNL.0b013e31828154f3>.



29. Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sorensen TI, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. *Mult Scler* (Houndmills, Basingstoke, England). 2013;19(10):1323–9. <https://doi.org/10.1177/1352458513483889>.
30. Tettey P, Simpson S, Taylor B, Ponsonby AL, Lucas RM, Dwyer T, et al. An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. *J Neurol Neurosurg Psychiatry*. 2017;88(5):395–401. <https://doi.org/10.1136/jnnp-2016-315037>.
31. Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, et al. Serum lipid profile changes predict neurodegeneration in interferon-beta1a-treated multiple sclerosis patients. *J Lipid Res*. 2017;58(2):403–11. <https://doi.org/10.1194/jlr.M072751>.
32. Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. *J Neurol Neurosurg Psychiatry*. 2013;84(11):1186–91. <https://doi.org/10.1136/jnnp-2012-304740>.
33. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. *J Neuroinflammation*. 2011;8:127-2094-8-127. <https://doi.org/10.1186/1742-2094-8-127>.
34. Altowajiri G. Dietary interventions and multiple sclerosis. *Curr Neurol Neurosci Rep*. 2017;17(3) <https://doi.org/10.1007/s11910-017-0732-3>.
35. Moss BP. Wellness and the role of comorbidities in multiple sclerosis. *Neurotherapeutics*. 14(4):999–1017. <https://doi.org/10.1007/s13311-017-0563-6>.
36. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “western-lifestyle” inflammatory diseases. *Immunity*. 2014;40(6):833–42. <https://doi.org/10.1016/j.immuni.2014.05.014>.
37. Moniri NH. Free-fatty acid receptor-4 (GPR120): Cellular and molecular function and its role in metabolic disorders. *Biochem Pharmacol*. 2016;110–111:1–15. <https://doi.org/10.1016/j.bcp.2016.01.021>.
38. Wirthgen E. Kynurenic acid: the Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. *Front Immunol*. 2017;8 <https://doi.org/10.3389/fimmu.2017.01957>.
39. McKenzie CI. GPR43—a prototypic metabolite sensor linking metabolic and inflammatory diseases. *Trends Endocrinol Metab*. 26(10):511–2. <https://doi.org/10.1016/j.tem.2015.07.009>.
40. Tao R. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat Med*. 13(11):1299–307. <https://doi.org/10.1038/nm1652>.
41. Gutiérrez-Vázquez C. Regulation of the immune response by the aryl hydrocarbon receptor. *Immunity* (Cambridge, Mass). 48(1): 19–33. <https://doi.org/10.1016/j.immuni.2017.12.012>.
42. Rothhammer V. Environmental control of autoimmune inflammation in the central nervous system. *Curre Opin Immunol*. 43:46–53. <https://doi.org/10.1016/j.coi.2016.09.002>.
43. Rothhammer V. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. *Nat Med*. 2016;22(6):586–97. <https://doi.org/10.1038/nm.4106>. **This study connects dietary tryptophan intake with effects inside the CNS mediated by the aryl hydrocarbon receptor.**
44. Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, Haque-Begum S, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. *J Immunol* (Baltimore, Md: 1950). 2009;183(10):6041–50. <https://doi.org/10.4049/jimmunol.0900747>. **This study first established the importance of gut microbiota in an animal model of MS.**
45. Ochoa-Reparaz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, et al. A polysaccharide from the human commensal *Bacteroides fragilis* protects against CNS demyelinating disease. *Mucosal Immunol*. 2010;3(5):487–95. <https://doi.org/10.1038/mi.2010.29>.
46. Berer K. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. *Proc Natl Acad Sci*. 2017;11233. <https://doi.org/10.1073/pnas.1711233114>.
47. Cekanaviciute E. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *Proc Natl Acad Sci*. 2017;11235. <https://doi.org/10.1073/pnas.1711235114>. **This study comprises the largest cohort to date studying the gut microbiota of untreated MS patients compared to healthy controls.**
48. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. *Nat Commun*. 2016;7:12015. <https://doi.org/10.1038/ncomms12015>.
49. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. *PloS One*. 2015;10(9): e0137429. <https://doi.org/10.1371/journal.pone.0137429>.
50. Chen JJ. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Sci Rep*. 6(1):28484. <https://doi.org/10.1038/srep28484>.
51. Libbey JE. Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis model. *Benefic Microbes*:1–20. <https://doi.org/10.3920/BM2017.0116>.
52. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. *Nature*. 2011;478(7368):250–4. <https://doi.org/10.1038/nature10434>.
53. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006;124(4):783–801.
54. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, et al. Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics*. 2006;118(2):511–21. <https://doi.org/10.1542/peds.2005-2824>.
55. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol*. 2008;6(11):e280. <https://doi.org/10.1371/journal.pbio.0060280>.
56. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci U S A*. 2011;108(Suppl 1):4554–61. <https://doi.org/10.1073/pnas.1000087107>.
57. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* (New York, NY). 2011;334(6052):105–8. <https://doi.org/10.1126/science.1208344>. **This study establishes the import influence of dietary habits on gut microbial composition.**
58. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. *Science* (New York, NY). 2013;341(6141):1237439. <https://doi.org/10.1126/science.1237439>.
59. Ruiz-Núñez B. The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease. *J Nutr Biochem*. 2016;36:1–20. <https://doi.org/10.1016/j.jnutbio.2015.12.007>.

60. Huang S. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. *J Lipid Res.* 53(9):2002–13. <https://doi.org/10.1194/jlr.D029546>.
61. Mani V. Dietary oil composition differentially modulates intestinal endotoxin transport and postprandial endotoxemia. *Nutr Metabol.* 10(1) <https://doi.org/10.1186/1743-7075-10-6>.
62. Timmermans S. High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the renin-angiotensin system. *J Neuroimmune Pharmacol.* 9(2):209–17. <https://doi.org/10.1007/s11481-013-9502-4>.
63. Haghikia A, Jorg S, Duscha A, Berg J, Manzel A, Waschbisch A, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. *Immunity.* 2015;43(4):817–29. <https://doi.org/10.1016/j.immuni.2015.09.007>.
64. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature.* 2013;504(7480):446–50. <https://doi.org/10.1038/nature12721>.
65. Swank RL. Multiple sclerosis; a correlation of its incidence with dietary fat. *Am J Med Sci.* 220(4):421–30.
66. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. *Lancet.* 1990;336(8706):37–9. **This paper reports long-term results of Swank's interventional study of a low-saturated fat diet in MS.**
67. Swank RL. Review of MS patient survival on a Swank low saturated fat diet. *Nutrition (Burbank, Los Angeles County, Calif.)* 19(2):161–2.
68. Azary S. Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 89(1):28–33. <https://doi.org/10.1136/jnnp-2017-315936>. **Prospective study in pediatric MS suggesting a negative impact of saturated fats and a benefit for vegetable intake.**
69. von Geldern G, Mowry EM. The influence of nutritional factors on the prognosis of multiple sclerosis. *Nat Rev Neurol.* 2012;8(12):678–89. <https://doi.org/10.1038/nrneurol.2012.194>.
70. Unoda K, Doi Y, Nakajima H, Yamane K, Hosokawa T, Ishida S, et al. Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis. *J Neuroimmunol.* 2013;256(1–2):7–12. <https://doi.org/10.1016/j.jneuroim.2012.12.003>.
71. Salvati S, Di Biase A, Attorri L, Di Benedetto R, Sanchez M, Lorenzini L, et al. Ethyl-eicosapentaenoic acid ameliorates the clinical course of experimental allergic encephalomyelitis induced in dark agouti rats. *J Nutr Biochem.* 2013;24(9):1645–54. <https://doi.org/10.1016/j.jnutbio.2013.02.005>.
72. Di Biase A, Salvati S, Di Benedetto R, Attorri L, Martinelli A, Malchiodi F. Eicosapentaenoic acid pre-treatment reduces biochemical changes induced in total brain and myelin of weanling Wistar rats by cuprizone feeding. *Prostaglandins Leukot Essent Fat Acids.* 2014;90(4):99–104. <https://doi.org/10.1016/j.plefa.2013.11.004>.
73. Torkildsen O, Brunborg LA, Thorsen F, Mork SJ, Stangel M, Myhr KM, et al. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. *Exp Neurol.* 2009;215(1):160–6. <https://doi.org/10.1016/j.expneurol.2008.09.026>.
74. Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. *Am J Epidemiol.* 2000;152(11):1056–64.
75. Bjørnevik K. Polyunsaturated fatty acids and the risk of multiple sclerosis. *Mult Scler.* 23(14):1830–8. <https://doi.org/10.1177/1352458517691150>.
76. Baarmhiel M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. *Mult Scler (Houndmills, Basingstoke, England).* 2014;20(6):726–32. <https://doi.org/10.1177/1352458513509508>.
77. Hoare S, Lithander F, van der Mei I, Ponsonby AL, Lucas R, Ausimmune Investigator G. Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: results from the Ausimmune Study. *Multiple sclerosis (Houndmills, Basingstoke, England).* 2015;
78. Langer-Gould A, editor. Fresh fish consumption is associated with a lower risk of multiple sclerosis independent of serum 25OHD levels. Paris: ECTRIMS; 2017.
79. Bates D. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 52(1):18–22.
80. Bates D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. *Br Med J.* 2(6149):1390–1.
81. Bates D. Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. *Br Med J.* 2(6092):932–3.
82. Torkildsen O.  $\omega$ -3 Fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. *Arch Neurol (Chicago).* 2012;69(8):1044–51.
83. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins Leukot Essent Fat Acids.* 2005;73(5):397–404.
84. Gu Y. Dietary patterns in Alzheimer's disease and cognitive aging. *Curr Alzheimer Res.* 8(5):510–9.
85. Gu YY. Mediterranean diet and brain structure in a multiethnic elderly cohort. *Neurology.* 85(20):1744–51. <https://doi.org/10.1212/WNL.0000000000002121>. **This paper establishes the impact of Mediterranean diet adherence on structural imaging metrics associated with cognitive decline.**
86. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. *Neurology.* 2004;62(1):60–5.
87. Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. *JAMA Neurol.* 2014;71(3):306–14. <https://doi.org/10.1001/jamaneurol.2013.5993>.
88. Munger KL, Chitnis T, Frazier AL, Giovannucci E, Spiegelman D, Ascherio A. Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. *J Neurol.* 2011;258(3):479–85. <https://doi.org/10.1007/s00415-010-5783-1>.
89. Banwell B, Bar-Or A, Cheung R, Kennedy J, Krupp LB, Becker DJ, et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. *Ann Neurol.* 2008;63(1):98–111. <https://doi.org/10.1002/ana.21244>.
90. Winer S, Astsaturov I, Cheung RK, Schrade K, Gunaratnam L, Wood DD, et al. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. *J Immunol (Baltimore, Md: 1950).* 2001;166(7):4751–6.
91. Stefferl A, Schubart A, Storch M, Amini A, Mather I, Lassmann H, et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. *J Immunol (Baltimore, Md: 1950).* 2000;165(5):2859–65.
92. Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. *J Immunol (Baltimore, Md: 1950).* 2004;172(1):661–8.
93. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in H110-/- mice. *Nature.* 2012;487(7405):104–8. <https://doi.org/10.1038/nature11225>.
94. Hadjkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. The association of diet with quality of life, disability, and relapse rate in an international sample of people

- with multiple sclerosis. *Nutr Neurosci*. 2014; <https://doi.org/10.1179/1476830514Y.0000000117>. **Registry-based study suggesting links between various dietary factors and MS severity.**
- 95.●● Fitzgerald KC. Diet quality is associated with disability and symptom severity in multiple sclerosis. *Neurology*. 90(1):e1–e11. <https://doi.org/10.1212/WNL.0000000000004768>. **Registry-based study suggesting links between various dietary factors and MS severity.**
  96. Saresella M. Immunological and clinical effect of diet modulation of the gut microbiome in multiple sclerosis patients: a pilot study. *Front Immunol*. 2017;8 <https://doi.org/10.3389/fimmu.2017.01391>.
  97. Vinolo MAR. Regulation of inflammation by short chain fatty acids. *Nutrients*. 2011;3(10):858–76. <https://doi.org/10.3390/nu3100858>.
  98. Xue Z. Mechanisms and therapeutic prospects of polyphenols as modulators of the aryl hydrocarbon receptor. *Food Funct*. 8(4): 1414–37.
  99. McKenzie C. The nutrition-gut microbiome-physiology axis and allergic diseases. *Immunol Rev*. 2017;278(1):277–95. <https://doi.org/10.1111/imr.12556>.
  - 100.●● Spagnuolo C. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. *Eur J Med Chem*. <https://doi.org/10.1016/j.ejmech.2017.09.001>. **Excellent review of the anti-inflammatory properties of flavonoids and their role in neurodegeneration.**
  101. Haghmorad D. Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis. *J Neuroimmunol*. 2017;302:23–33. <https://doi.org/10.1016/j.jneuroim.2016.11.009>.
  102. Wang J. Dietary naringenin supplementation attenuates experimental autoimmune encephalomyelitis by modulating autoimmune inflammatory responses in mice. *J Nutr Biochem*. 54:130–9. <https://doi.org/10.1016/j.jnutbio.2017.12.004>.
  103. Hashimoto M. The flavonoid Baicalein attenuates cuprizone-induced demyelination via suppression of neuroinflammation. *Brain Res Bull*. 135:47–52. <https://doi.org/10.1016/j.brainresbull.2017.09.007>.
  104. Zhang Q. Myricetin alleviates cuprizone-induced behavioral dysfunction and demyelination in mice by Nrf2 pathway. *Food Funct*. 7(10):4332–42.
  105. Skaper SD. Co-ultramicrosized palmitoylethanolamide/luteolin facilitates the development of differentiating and undifferentiated rat oligodendrocyte progenitor cells. *Mol Neurobiol*. 55(1):103–14. <https://doi.org/10.1007/s12035-017-0722-0>.
  106. Zhang Y. Icarin enhances remyelination process after acute demyelination induced by cuprizone exposure. *Brain Res Bull*. 2017;130:180–7. <https://doi.org/10.1016/j.brainresbull.2017.01.025>.
  107. Joseph JA. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. *J Neurosci*. 19(18):8114–21.
  108. Miller MG. Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. *Eur J Nutr*. 57(3):1169–80. <https://doi.org/10.1007/s00394-017-1400-8>.
  109. Xin J, Feinstein DL, Hejna MJ, Lorens SA, McGuire SO. Beneficial effects of blueberries in experimental autoimmune encephalomyelitis. *J Agric Food Chem*. 2012;60(23):5743–8. <https://doi.org/10.1021/jf203611t>.
  110. Wu C, Yosef N, Thalhammer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. *Nature*. 2013;496(7446):513–7. <https://doi.org/10.1038/nature11984>.
  111. Kleinewietfeld M, Manzel A, Titze J, Kvakana H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. *Nature*. 2013;496(7446): 518–22. <https://doi.org/10.1038/nature11868>.
  112. Farez MF, Fiol MP, Gaitan MI, Quintana FJ, Correale J. Sodium intake is associated with increased disease activity in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2015;86(1):26–31. <https://doi.org/10.1136/jnnp-2014-307928>.
  113. McDonald J. A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. *Mult Scler Relat Disord*. 6:87–92. <https://doi.org/10.1016/j.msard.2016.02.011>.
  114. Nourbakhsh B. Dietary salt intake and time to relapse in paediatric multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2016;87(12): 1350–3. <https://doi.org/10.1136/jnnp-2016-313410>.
  115. Fitzgerald KC, et al. *Ann Neurol*. 82(1):20–9. <https://doi.org/10.1002/ana.24965>.
  116. Anderson RM. Caloric restriction research: new perspectives on the biology of aging. *J Gerontol A Biol Sci Med Sci*. 73(1):1–3. <https://doi.org/10.1093/gerona/glx212>.
  117. Esquifino AI. Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction. *J Physiol Biochem*. 60(4):245–52.
  118. Esquifino AI. Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction. *J Neuroinflamm*. 4(1) <https://doi.org/10.1186/1742-2094-4-6>.
  119. Piccio L. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. *J Leukoc Biol*. 84(4):940–8. <https://doi.org/10.1189/jlb.0208133>.
  120. Kafami L. Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice. *Avicenna J Med Biotechnol*. 2(1):47–52.
  121. Choi IY. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. *Cell Rep (Cambridge)*. 2016;15(10):2136–46. <https://doi.org/10.1016/j.celrep.2016.05.009>.
  122. Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, et al. Effects of a low fat plant based diet in multiple sclerosis (MS): results of a 1-year long randomized controlled (RC) study (P6.152). *Neurology*. 2014;82(10 Supplement):P6.152–P6.
  123. Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, et al. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. *J Altern Complement Med (New York, NY)*. 2014;20(5):347–55. <https://doi.org/10.1089/acm.2013.0188>.
  124. Gardener S. Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population. *Transl Psychiatry*. 2(10): e164. <https://doi.org/10.1038/tp.2012.91>.